机构:[1]Hebei Clinical Research Center for Chronic Kidney Disease, Hebei Key Laboratory of Vascular Calcification in Kidney Disease, Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.临床科室肾内科河北医科大学第四医院
Previous studies have shown that the apoptosis of vascular smooth muscle cells (VSMCs) underlies the mechanism of pathological calcification in patients with chronic kidney disease (CKD). SET domain-containing protein 8 (SET8) is an efficient protein that modulates apoptosis in hepatocellular carcinoma cells, esophageal squamous cells, and neuronal cells by regulating pathological processes, such as cell cycle progression and transcription regulation. However, whether SET8 is involved in high phosphorus-induced vascular calcification by mediating apoptosis remains unclear. Here, we report that SET8 is located both in the nucleus and cytoplasm and is significantly downregulated in calcification models. SET8 deficiency promoted apoptosis of VSMCs, as indicated by the increased Bax/Bcl-2 and cleaved caspase-3/total caspase-3 ratios. Mechanistically, the PI3K/Akt pathway was mediated by SET8, and inhibition of the PI3K/Akt signaling pathway by administering LY294002 or transfecting the Akt phosphorylation-inactivated mutation plasmid increased apoptosis and calcification. Akt phosphorylation constitutively activated mutations can reduce the apoptosis and calcification of VSMCs. Furthermore, exogenous overexpression of SET8 reversed the effect of PI3K/Akt inhibition on VSMC apoptosis and calcification. In summary, our research suggests that SET8 overexpression ameliorates high phosphorus-induced calcification of VSMCs by activating PI3K/Akt mediated anti-apoptotic effects.
基金:
This work was supported by The Project of Hebei Clinical Medicine Outstanding Personnel
Training (grant. no. 2019139), Hebei province medical technology tracking project (G2018050) and
Hebei province Key research and development Project (20377704D).
第一作者机构:[1]Hebei Clinical Research Center for Chronic Kidney Disease, Hebei Key Laboratory of Vascular Calcification in Kidney Disease, Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.
共同第一作者:
通讯作者:
通讯机构:[1]Hebei Clinical Research Center for Chronic Kidney Disease, Hebei Key Laboratory of Vascular Calcification in Kidney Disease, Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.[*1]Department of Nephrology, the Fourth Hospital of Hebei Medical University 12 Jiankang Road, Shijiazhuang, 050011, P. R. China
推荐引用方式(GB/T 7714):
Bai Yaling,Cheng Meijuan,Jin Jingjing,et al.SET8, a novel regulator to ameliorate vascular calcification via activating PI3K/Akt mediated anti-apoptotic effects.[J].BIOCHEMISTRY AND CELL BIOLOGY.2022,100(2):104-114.doi:10.1139/bcb-2021-0322.
APA:
Bai Yaling,Cheng Meijuan,Jin Jingjing,Zhang Huiran,He Lei...&Xu Jinsheng.(2022).SET8, a novel regulator to ameliorate vascular calcification via activating PI3K/Akt mediated anti-apoptotic effects..BIOCHEMISTRY AND CELL BIOLOGY,100,(2)
MLA:
Bai Yaling,et al."SET8, a novel regulator to ameliorate vascular calcification via activating PI3K/Akt mediated anti-apoptotic effects.".BIOCHEMISTRY AND CELL BIOLOGY 100..2(2022):104-114